Our mission is to develop novel immunotherapies for cancer. Our research focuses on understanding the mechanisms that contribute to an immune suppressive tumor microenvironment (TME) in treatment resistant cancers biased by sex immune dimorphism and utilizing targeted therapies to reshape the immune regulatory TME. We also investigate innate immune memory mechanisms to equip Natural killer cells (NK cells) with immune memory features against solid tumors.
Photo: Dhifaf SarhanThe Tumor Immunology & Immunotherapy Group aim to fill the knowledge gap about differences in sex-specific immune responses and how these contribute to the response to immunotherapy.
Photo: Dhifaf Sarhan.The Tumor Immunology & Immunotherapy Group's exploration of a new subset of NK cells so called adaptive NK cells (aNK cells) in solid tumors.
Photo: Getty Images,Getty Images/iStockphotoImmunotherapy for pancreatic cancer has limited effect and differs between men and women. KI researchers have now found a possible explanation for this sex difference.
Photo: Stefan ZimmermanDhifaf Sarhan, PhD, Karolinska Institute, Stockholm, Sweden, discusses the differences in the tumor microenvironment between female and male patients with pancreatic cancer at the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.
Immunotherapy is an effective form of therapy for different types of cancer, but for pancreatic cancer, its effect is limited and differs between men and women. Researchers at Karolinska Institutet have now found a possible explanation for this sex difference.
We are always looking for brilliant minds to join our group. Don’t hesitate to contact us for job, thesis work, and internship opportunities.
